Extracellular Vesicle Therapy for Type 1 Diabetes

Setareh Soltani; Kamran Mansouri; Mohammad Sajad Emami Aleagha; Narges Moasefi; Niloofar Yavari; Seyed Kazem Shakouri; Sara Notararigo; Ali Shojaeian; Flemming Pociot; Reza Yarani

doi:10.3389/fimmu.2022.865782

Extracellular Vesicle Therapy for Type 1 Diabetes

Setareh Soltani, Kamran Mansouri, Mohammad Sajad Emami Aleagha, Narges Moasefi, Niloofar Yavari, Seyed Kazem Shakouri, Sara Notararigo, Ali Shojaeian, Flemming Pociot, Reza Yarani

Steno Diabetes Center Copenhagen

19 Citationer (Scopus)

Abstract

Type 1 diabetes (T1D) is a chronic disorder characterized by immune-mediated destruction of pancreatic insulin-producing β-cells. The primary treatment for T1D is multiple daily insulin injections to control blood sugar levels. Cell-free delivery packets with therapeutic properties, extracellular vesicles (EVs), mainly from stem cells, have recently gained considerable attention for disease treatments. EVs provide a great potential to treat T1D ascribed to their regenerative, anti-inflammatory, and immunomodulatory effects. Here, we summarize the latest EV applications for T1D treatment and highlight opportunities for further investigation.

Originalsprog	Engelsk
Artikelnummer	865782
Tidsskrift	Frontiers in Immunology
Vol/bind	13
Sider (fra-til)	865782
ISSN	1664-3224
DOI	https://doi.org/10.3389/fimmu.2022.865782
Status	Udgivet - 8 apr. 2022

Adgang til dokumentet

10.3389/fimmu.2022.865782

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{5feb606a776f43479aa402d9a0ca904e,

title = "Extracellular Vesicle Therapy for Type 1 Diabetes",

abstract = "Type 1 diabetes (T1D) is a chronic disorder characterized by immune-mediated destruction of pancreatic insulin-producing β-cells. The primary treatment for T1D is multiple daily insulin injections to control blood sugar levels. Cell-free delivery packets with therapeutic properties, extracellular vesicles (EVs), mainly from stem cells, have recently gained considerable attention for disease treatments. EVs provide a great potential to treat T1D ascribed to their regenerative, anti-inflammatory, and immunomodulatory effects. Here, we summarize the latest EV applications for T1D treatment and highlight opportunities for further investigation.",

keywords = "Diabetes Mellitus, Type 1/therapy, Extracellular Vesicles, Humans, Immunomodulation, Insulin, Insulin-Secreting Cells",

author = "Setareh Soltani and Kamran Mansouri and {Emami Aleagha}, {Mohammad Sajad} and Narges Moasefi and Niloofar Yavari and Shakouri, {Seyed Kazem} and Sara Notararigo and Ali Shojaeian and Flemming Pociot and Reza Yarani",

note = "Copyright {\textcopyright} 2022 Soltani, Mansouri, Emami Aleagha, Moasefi, Yavari, Shakouri, Notararigo, Shojaeian, Pociot and Yarani.",

year = "2022",

month = apr,

day = "8",

doi = "10.3389/fimmu.2022.865782",

language = "English",

volume = "13",

pages = "865782",

journal = "Frontiers in Immunology",

issn = "1664-3224",

publisher = "Frontiers Media S.A.",

}

TY - JOUR

T1 - Extracellular Vesicle Therapy for Type 1 Diabetes

AU - Soltani, Setareh

AU - Mansouri, Kamran

AU - Emami Aleagha, Mohammad Sajad

AU - Moasefi, Narges

AU - Yavari, Niloofar

AU - Shakouri, Seyed Kazem

AU - Notararigo, Sara

AU - Shojaeian, Ali

AU - Pociot, Flemming

AU - Yarani, Reza

PY - 2022/4/8

Y1 - 2022/4/8

N2 - Type 1 diabetes (T1D) is a chronic disorder characterized by immune-mediated destruction of pancreatic insulin-producing β-cells. The primary treatment for T1D is multiple daily insulin injections to control blood sugar levels. Cell-free delivery packets with therapeutic properties, extracellular vesicles (EVs), mainly from stem cells, have recently gained considerable attention for disease treatments. EVs provide a great potential to treat T1D ascribed to their regenerative, anti-inflammatory, and immunomodulatory effects. Here, we summarize the latest EV applications for T1D treatment and highlight opportunities for further investigation.

AB - Type 1 diabetes (T1D) is a chronic disorder characterized by immune-mediated destruction of pancreatic insulin-producing β-cells. The primary treatment for T1D is multiple daily insulin injections to control blood sugar levels. Cell-free delivery packets with therapeutic properties, extracellular vesicles (EVs), mainly from stem cells, have recently gained considerable attention for disease treatments. EVs provide a great potential to treat T1D ascribed to their regenerative, anti-inflammatory, and immunomodulatory effects. Here, we summarize the latest EV applications for T1D treatment and highlight opportunities for further investigation.

KW - Diabetes Mellitus, Type 1/therapy

KW - Extracellular Vesicles

KW - Humans

KW - Immunomodulation

KW - Insulin

KW - Insulin-Secreting Cells

UR - http://www.scopus.com/inward/record.url?scp=85128616254&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2022.865782

DO - 10.3389/fimmu.2022.865782

M3 - Review

C2 - 35464488

SN - 1664-3224

VL - 13

SP - 865782

JO - Frontiers in Immunology

JF - Frontiers in Immunology

M1 - 865782

ER -

Extracellular Vesicle Therapy for Type 1 Diabetes

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater